MedTrace Logo

A Multi-Centre Study in Patients Undergoing Total Hip Arthroplasty With the Smith+Nephew CATALYSTEM™ Primary Hip System

NCT06564636 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 119

Last updated 2026-03-12

No results posted yet for this study

Summary

A Multi-Center Study in Patients Undergoing Total Hip Arthroplasty with the Smith+Nephew CATALYSTEM™ Primary Hip System. The purpose of the study is to assess safety and performance of the CATALYSTEM™ and to support product approval in global markets.

Conditions

  • Total Hip Arthroplasty (THA)
  • Osteoarthritis
  • Degenerative Joint Disease
  • Inflammatory Arthritis
  • Avascular Necrosis
  • Post-traumatic Arthritis
  • Congenital Hip Dysplasia

Interventions

DEVICE

CATALYSTEM

CATALYSTEM Cementless Primary Hip System for participants with Total Hip Arthroplasty

Sponsors & Collaborators

  • Smith & Nephew, Inc.

    lead INDUSTRY

Principal Investigators

  • Rachel Jahnke · Smith & Nephew, Inc.

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-26
Primary Completion
2027-12-31
Completion
2036-03-31
FDA Device
Yes

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06564636 on ClinicalTrials.gov